Figure 4: The emission profiles and the tissue penetration assessment.
From: In vivo nanoparticle-mediated radiopharmaceutical-excited fluorescence molecular imaging
(a) The emission spectra of 18F-FDG, 18F-FDG+EO, 131I-NaI, 131I-NaI+EO, 99mTc-MDP+EO and PBS (each radiotracer, 140 μCi; EO, 10 mg). The spectra of 18F-FDG and 131I-NaI indicate the Cerenkov light is weighted towards blue (< 500 nm), and the spectra of 18F-FDG+EO, 131I-NaI+EO and 99mTc-MDP+EO show a similar profile with peak emission at 620 nm. The EO absorbance of part of the Cerenkov light is indicated by the difference between the emission spectra of radiotracer with and without EO from the wavelength of 500–570 nm. (b,c) The comparison between Cerenkov luminescence (Control, 50 μCi 18F-FDG) and 18F-FDG radiation-excited fluorescence (well 1–4) before (b) and after (c) covering with a piece of 1-mm thick porcine gastric mucosa tissue. (d) The quantification of the optical intensity of each well after covering the tissue.
